Aakha Biologics Announces Licensing Agreement with March Biosciences to Advance Cell Therapy Development

Aakha Biologics, (“Aakha”), a biotechnology company building multi-specific antibodies for cancer and autoimmune diseases, has announced it has licensed one of its proprietary antibodies to March Biosciences, (“March”),  a clinical stage biotechnology company dedicated to treating cancers resistant to current immunotherapies. March will integrate the antibody sequence into their expanding cell therapies pipeline. Under the terms of the agreement, Aakha will receive an upfront payment from March and be eligible for near-term preclinical milestone payments, as well as potential future milestone payments and royalties.

 

Aakha Biologics is advancing a pipeline of first-in-class immune engager antibody therapies, engineered for precision, potency, and safety, with strong potential for clinical translation. These therapies are designed to offer innovative treatment options for patients with cancer and other serious diseases. By leveraging Aakha’s de novo antibody sequence, the collaboration enables March to accelerate the development of novel treatments for patients in need.

 

“We’re thrilled to collaborate with March Biosciences as they incorporate our antibody into their novel cell therapy approach,” said Hemanta Baruah, Chief Executive Officer, Aakha Biologics. “This collaboration validates the strength of our platform and supports our mission to deliver impactful immune-based treatments to patients.”

 

“We are excited to collaborate with Aakha to build new cutting-edge cell therapies,” said Sarah Hein, Chief Executive Officer of March Biosciences. “Aakha’s technology enhances our capabilities as we develop new therapeutic strategies to address additional difficult to treat cancers where patients have limited options.”

 

Aakha Biologics is a portfolio company of 82VS, the venture studio of Alloy Therapeutics. Aakha leverages Alloy’s discovery platforms and expertise to accelerate its pipeline of antibody-based immuno-oncology therapies. 82VS empowers scientist-entrepreneurs to build therapeutic drug companies by supporting teams from ideation through company creation, discovery, financing, and scaling.

 

​

About March Biosciences

Houston-based March Biosciences, launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital), is dedicated to addressing challenging cancers unresponsive to current immunotherapies. Its lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 2 clinical development for patients with relapsed / refractory T-cell lymphoma. Learn more at www.march.bio

 

About Aakha Biologics

Aakha Biologics is a biotechnology company focused on the development of next-generation immunotherapies for the treatment of cancer. By utilizing advanced antibody engineering and developing novel immune engagers to deliver breakthrough solutions that improve patient outcomes and quality of life. For more information, please visit www.aakha.bio

​

About 82VS

82VS is the venture studio of Alloy Therapeutics, empowering exceptional scientist-entrepreneurs building therapeutic drug companies leveraging Alloy’s platforms and services. Aligned with the collaborative ecosystem ethos at Alloy, 82VS looks to partner and collaborate at every stage of the process supporting teams from ideation through to company creation, discovery, financing, and scaling of their businesses. For more information visit www.82vs.com

 

 

Media Contact

Hemanta Baruah
CEO, Aakha Biologics
Email: hemanta.baruah@aakha.bio